Picoplatin: Phase III data

The open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care missed the

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE